Form 8-K - Current report:
SEC Accession No. 0001610618-25-000072
Filing Date
2025-06-20
Accepted
2025-06-20 16:37:33
Documents
14
Period of Report
2025-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20250618.htm   iXBRL 8-K 51121
2 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION exhibit312025-06x20.htm EX-3.1 9462
3 2024 EQUITY INCENTIVE PLAN exhibit1012025-06x20.htm EX-10.1 334327
  Complete submission text file 0001610618-25-000072.txt   579721

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20250618.xsd EX-101.SCH 1780
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20250618_lab.xml EX-101.LAB 23707
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20250618_pre.xml EX-101.PRE 13583
16 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20250618_htm.xml XML 2929
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 251061978
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)